The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andreae, S.
Right arrow Articles by Triebel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andreae, S.
Right arrow Articles by Triebel, F.
The Journal of Immunology, 2002, 168: 3874-3880.
Copyright © 2002 by The American Association of Immunologists

Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)1

Susanne Andreae*, Fabienne Piras{dagger}, Nicolas Burdin{dagger} and Frédéric Triebel2,*

* Laboratoire d’Immunologie des Tumeurs, Université Paris-Sud, Chatenay Malabry, France; and {dagger} Aventis-Pasteur, Marcy L’Etoile, France

Lymphocyte activation gene-3 (LAG-3) is an MHC class II ligand expressed on activated T and NK cells. A LAG-3Ig fusion protein has been used in mice as an adjuvant protein to induce antitumor responses and specific CD8 and CD4 Th1 responses to nominal Ags. In this work we report on the effect of LAG-3Ig on the maturation and activation of human monocyte-derived dendritic cells (DC). LAG-3Ig binds MHC class II molecules expressed in plasma membrane lipid rafts on immature human DC and induces rapid morphological changes, including the formation of dendritic projections. LAG-3Ig markedly up-regulates the expression of costimulatory molecules and the production of IL-12 and TNF-{alpha}. Consistent with this effect on DC maturation, LAG-3Ig disables DC in their capacity to capture soluble Ags. These events are associated with the acquisition of professional APC function, because LAG-3Ig increases the capacity of DC to stimulate the proliferation and IFN-{gamma} response by allogeneic T cells. These effects were not observed when using ligation of MHC class II by specific mAb. Class II-mediated signals induced by a natural ligand, LAG-3, lead to complete maturation of DC, which acquire the capacity to trigger naive T cells and drive polarized Th1 responses.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. Brignone, B. Escudier, C. Grygar, M. Marcu, and F. Triebel
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Clin. Cancer Res., October 1, 2009; 15(19): 6225 - 6231.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Li, M. VanRoey, F. Triebel, and K. Jooss
Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy
Clin. Cancer Res., June 1, 2008; 14(11): 3545 - 3554.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Brignone, C. Grygar, M. Marcu, K. Schakel, and F. Triebel
A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells
J. Immunol., September 15, 2007; 179(6): 4202 - 4211.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
R. M. Srivastava, Ch. Varalakshmi, and A. Khar
Cross-linking a mAb to NKR-P2/NKG2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response
Int. Immunol., May 1, 2007; 19(5): 591 - 607.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Bayry, F. Triebel, S. V. Kaveri, and D. F. Tough
Human Dendritic Cells Acquire a Semimature Phenotype and Lymph Node Homing Potential through Interaction with CD4+CD25+ Regulatory T Cells
J. Immunol., April 1, 2007; 178(7): 4184 - 4193.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli
Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity.
Cancer Res., April 15, 2006; 66(8): 4450 - 4460.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
T. L. Herrmann, C. T. Morita, K. Lee, and D. J. Kusner
Calmodulin kinase II regulates the maturation and antigen presentation of human dendritic cells
J. Leukoc. Biol., December 1, 2005; 78(6): 1397 - 1407.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Li, C. J. Workman, S. M. Martin, and D. A. A. Vignali
Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)
J. Immunol., December 1, 2004; 173(11): 6806 - 6812.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Andreae, S. Buisson, and F. Triebel
MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)
Blood, September 15, 2003; 102(6): 2130 - 2137.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
N. Setterblad, C. Roucard, C. Bocaccio, J.-P. Abastado, D. Charron, and N. Mooney
Composition of MHC class II-enriched lipid microdomains is modified during maturation of primary dendritic cells
J. Leukoc. Biol., July 1, 2003; 74(1): 40 - 48.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Cappello, F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P.-L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli, et al.
LAG-3 Enables DNA Vaccination to Persistently Prevent Mammary Carcinogenesis in HER-2/neu Transgenic BALB/c Mice
Cancer Res., May 15, 2003; 63(10): 2518 - 2525.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.